SCHEMBL31104264

SCHEMBL31104264

CC(=O)CCc1cnn(C2CCCCO2)c(=O)c1Cl

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 0.38
▸ LMNA P02545 2/20 0.38
▸ POLB P06746 1/20 0.38
▸ RXRA P19793 1/20 0.38
▸ RXRB P28702 1/20 0.38
▸ RXRG P48443 1/20 0.38
▸ CNR2 P34972 1/20 0.37
▸ CYP4F2 P78329 3/20 0.36
▸ CYP4A11 Q02928 3/20 0.36
▸ RAB9A P51151 3/20 0.34
▸ MITF O75030 2/20 0.34
▸ NPC1 O15118 1/20 0.34
▸ PAX8 Q06710 1/20 0.34
▸ SMN1; SMN2 Q16637 2/20 0.33
▸ MAPT P10636 1/20 0.33
▸ HTT P42858 1/20 0.33
▸ RECQL P46063 1/20 0.33
▸ MDM2 Q00987 1/20 0.33
▸ GAA P10253 1/20 0.33
▸ YTHDC1 Q96MU7 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25342197 0.88 RXRA (0.41) ALDH1A1LMNAPOLBRXRARXRB
SCHEMBL31386712 0.86 ALDH1A1 (0.41) ALDH1A1LMNAPOLBRXRARXRB
SCHEMBL31103869 0.84 RXRA (0.35) ALDH1A1LMNAPOLBRXRARXRB
SCHEMBL31104026 0.84 ALDH1A1 (0.40) ALDH1A1LMNAPOLBRXRARXRB
SCHEMBL31103927 0.81 ALDH1A1 (0.42) ALDH1A1LMNAPOLBRXRARXRB
SCHEMBL31103775 0.81 ALDH1A1 (0.40) ALDH1A1LMNAPOLBRXRARXRB
SCHEMBL31104446 0.79 ALDH1A1 (0.41) ALDH1A1LMNAPOLBRXRARXRB
SCHEMBL31104090 0.78 SLC6A3 (0.39) ALDH1A1LMNAPOLBRXRARXRB
SCHEMBL24177147 0.78 ALDH1A1 (0.39) ALDH1A1LMNAPOLBRXRARXRB
SCHEMBL25341195 0.78 RXRA (0.42) ALDH1A1LMNAPOLBRXRARXRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250059161-A1 COMPOUNDS AND METHODS FOR MODULATING STAT3 VIVIDION THERAPEUTICS, INC. 2025-02-20 — — US disclosed
WO-2024182693-A1 2-AZASPIRO[3.3]HEPTANE DERIVATIVES AS STAT3 INHIBITORS FOR THE TREATMENT OF CANCER VIVIDION THERAPEUTICS, INC. (US) 2024-09-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250059161-A1 COMPOUNDS AND METHODS FOR MODULATING STAT3 STAT3, JAK2, STAT1 ALDH1A1 2652/4885LMNA 4098/4885POLB 3690/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback